APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vaginosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vaginosis Drug Market Outlook and Growth Opportunities 2026

22 December 2025203 pages

Choose your research edition.

Industry ResearchVaginosis Drug Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaginosis Drug Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Vaginosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaginosis Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaginosis Drug Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Vaginosis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vaginosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vaginosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vaginosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vaginosis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vaginosis Drug market include Yunnan Baiyao, Abbott, Xiuzheng, Teva, Sanofi, Pfizer, Bayer, West-Ward and Starpharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vaginosis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vaginosis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaginosis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vaginosis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Vaginosis Drug Segment by Company

Yunnan Baiyao

Abbott

Xiuzheng

Teva

Sanofi

Pfizer

Bayer

West-Ward

Starpharma

Piramal

Perrigo

Novel

Mission

HPGC

Galderma

Edenvridge

Alkem

Vaginosis Drug Segment by Type

Rx

OTC

Vaginosis Drug Segment by Application

Hospital

Pharmacy

Other

Vaginosis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Vaginosis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Vaginosis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vaginosis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Vaginosis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaginosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaginosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaginosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vaginosis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaginosis Drug industry.

Chapter 3: Detailed analysis of Vaginosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Vaginosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Vaginosis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vaginosis Drug Industry Trends Table 2. Vaginosis Drug Industry Drivers Table 3. Vaginosis Drug Industry Opportunities and Challenges Table 4. Vaginosis Drug Industry Restraints Table 5. Global Vaginosis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vaginosis Drug Revenue Share by Company (2021-2026) Table 7. Global Vaginosis Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Vaginosis Drug Sales Volume Share by Company (2021-2026) Table 9. Global Vaginosis Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Vaginosis Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Vaginosis Drug Key Company Manufacturing Base & Headquarters Table 12. Global Vaginosis Drug Company, Product Type & Application Table 13. Global Vaginosis Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Vaginosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Rx Table 18. Significant Companies of OTC Table 19. Global Vaginosis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Vaginosis Drug Sales Volume by Type (2021-2026) & (k units) Table 21. Global Vaginosis Drug Sales Volume by Type (2027-2032) & (k units) Table 22. Global Vaginosis Drug Sales Volume Share by Type (2021-2026) Table 23. Global Vaginosis Drug Sales Volume Share by Type (2027-2032) Table 24. Global Vaginosis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Vaginosis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Vaginosis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Vaginosis Drug Sales Value Share by Type (2021-2026) Table 28. Global Vaginosis Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Pharmacy Table 31. Significant Companies of Other Table 32. Global Vaginosis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Vaginosis Drug Sales Volume by Application (2021-2026) & (k units) Table 34. Global Vaginosis Drug Sales Volume by Application (2027-2032) & (k units) Table 35. Global Vaginosis Drug Sales Volume Share by Application (2021-2026) Table 36. Global Vaginosis Drug Sales Volume Share by Application (2027-2032) Table 37. Global Vaginosis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Vaginosis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Vaginosis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Vaginosis Drug Sales Value Share by Application (2021-2026) Table 41. Global Vaginosis Drug Sales Value Share by Application (2027-2032) Table 42. Global Vaginosis Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Vaginosis Drug Sales by Region (2021-2026) & (k units) Table 44. Global Vaginosis Drug Sales Market Share by Region (2021-2026) Table 45. Global Vaginosis Drug Sales by Region (2027-2032) & (k units) Table 46. Global Vaginosis Drug Sales Market Share by Region (2027-2032) Table 47. Global Vaginosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Vaginosis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Vaginosis Drug Sales Value Share by Region (2021-2026) Table 50. Global Vaginosis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Vaginosis Drug Sales Value Share by Region (2027-2032) Table 52. Global Vaginosis Drug Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Vaginosis Drug Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Vaginosis Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Vaginosis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Vaginosis Drug Sales by Country (2021-2026) & (k units) Table 57. Global Vaginosis Drug Sales Market Share by Country (2021-2026) Table 58. Global Vaginosis Drug Sales by Country (2027-2032) & (k units) Table 59. Global Vaginosis Drug Sales Market Share by Country (2027-2032) Table 60. Global Vaginosis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Vaginosis Drug Sales Value Market Share by Country (2021-2026) Table 62. Global Vaginosis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Vaginosis Drug Sales Value Market Share by Country (2027-2032) Table 64. Yunnan Baiyao Company Information Table 65. Yunnan Baiyao Business Overview Table 66. Yunnan Baiyao Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Yunnan Baiyao Vaginosis Drug Product Portfolio Table 68. Yunnan Baiyao Recent Development Table 69. Abbott Company Information Table 70. Abbott Business Overview Table 71. Abbott Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Abbott Vaginosis Drug Product Portfolio Table 73. Abbott Recent Development Table 74. Xiuzheng Company Information Table 75. Xiuzheng Business Overview Table 76. Xiuzheng Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Xiuzheng Vaginosis Drug Product Portfolio Table 78. Xiuzheng Recent Development Table 79. Teva Company Information Table 80. Teva Business Overview Table 81. Teva Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Teva Vaginosis Drug Product Portfolio Table 83. Teva Recent Development Table 84. Sanofi Company Information Table 85. Sanofi Business Overview Table 86. Sanofi Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Sanofi Vaginosis Drug Product Portfolio Table 88. Sanofi Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Pfizer Vaginosis Drug Product Portfolio Table 93. Pfizer Recent Development Table 94. Bayer Company Information Table 95. Bayer Business Overview Table 96. Bayer Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Bayer Vaginosis Drug Product Portfolio Table 98. Bayer Recent Development Table 99. West-Ward Company Information Table 100. West-Ward Business Overview Table 101. West-Ward Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. West-Ward Vaginosis Drug Product Portfolio Table 103. West-Ward Recent Development Table 104. Starpharma Company Information Table 105. Starpharma Business Overview Table 106. Starpharma Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Starpharma Vaginosis Drug Product Portfolio Table 108. Starpharma Recent Development Table 109. Piramal Company Information Table 110. Piramal Business Overview Table 111. Piramal Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Piramal Vaginosis Drug Product Portfolio Table 113. Piramal Recent Development Table 114. Perrigo Company Information Table 115. Perrigo Business Overview Table 116. Perrigo Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Perrigo Vaginosis Drug Product Portfolio Table 118. Perrigo Recent Development Table 119. Novel Company Information Table 120. Novel Business Overview Table 121. Novel Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Novel Vaginosis Drug Product Portfolio Table 123. Novel Recent Development Table 124. Mission Company Information Table 125. Mission Business Overview Table 126. Mission Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Mission Vaginosis Drug Product Portfolio Table 128. Mission Recent Development Table 129. HPGC Company Information Table 130. HPGC Business Overview Table 131. HPGC Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. HPGC Vaginosis Drug Product Portfolio Table 133. HPGC Recent Development Table 134. Galderma Company Information Table 135. Galderma Business Overview Table 136. Galderma Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Galderma Vaginosis Drug Product Portfolio Table 138. Galderma Recent Development Table 139. Edenvridge Company Information Table 140. Edenvridge Business Overview Table 141. Edenvridge Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Edenvridge Vaginosis Drug Product Portfolio Table 143. Edenvridge Recent Development Table 144. Alkem Company Information Table 145. Alkem Business Overview Table 146. Alkem Vaginosis Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Alkem Vaginosis Drug Product Portfolio Table 148. Alkem Recent Development Table 149. Key Raw Materials Table 150. Raw Materials Key Suppliers Table 151. Vaginosis Drug Distributors List Table 152. Vaginosis Drug Customers List Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Vaginosis Drug Product Image Figure 2. Global Vaginosis Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaginosis Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Vaginosis Drug Sales (2021-2032) & (k units) Figure 5. Global Vaginosis Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Vaginosis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Rx Image Figure 10. OTC Image Figure 11. Global Vaginosis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Vaginosis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Vaginosis Drug Sales Volume Share by Type (2021-2032) Figure 14. Global Vaginosis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Vaginosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Vaginosis Drug Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmacy Image Figure 19. Other Image Figure 20. Global Vaginosis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Vaginosis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Vaginosis Drug Sales Volume Share by Application (2021-2032) Figure 23. Global Vaginosis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Vaginosis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Vaginosis Drug Sales Value Share by Application (2021-2032) Figure 26. Global Vaginosis Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Vaginosis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Vaginosis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Vaginosis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Vaginosis Drug Sales Value (2021-2032) & (US$ Million) Figure 31. North America Vaginosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Vaginosis Drug Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Vaginosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Vaginosis Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Vaginosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Vaginosis Drug Sales Value (2021-2032) & (US$ Million) Figure 37. South America Vaginosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Vaginosis Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Vaginosis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Vaginosis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Vaginosis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Vaginosis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Vaginosis Drug Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Vaginosis Drug Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Rx
  • OTC
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Yunnan Baiyao
  • Abbott
  • Xiuzheng
  • Teva
  • Sanofi
  • Pfizer
  • Bayer
  • West-Ward
  • Starpharma
  • Piramal
  • Perrigo
  • Novel
  • Mission
  • HPGC
  • Galderma
  • Edenvridge
  • Alkem

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vaginosis Drug Sales Value (2021-2032)
  4. 1.2.2 Global Vaginosis Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Vaginosis Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Vaginosis Drug Market Dynamics
  1. 2.1 Vaginosis Drug Industry Trends
  2. 2.2 Vaginosis Drug Industry Drivers
  3. 2.3 Vaginosis Drug Industry Opportunities and Challenges
  4. 2.4 Vaginosis Drug Industry Restraints
3 Vaginosis Drug Market by Company
  1. 3.1 Global Vaginosis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Vaginosis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Vaginosis Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Vaginosis Drug Average Price by Company (2021-2026)
  5. 3.5 Global Vaginosis Drug Company Ranking (2024-2026)
  6. 3.6 Global Vaginosis Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Vaginosis Drug Company Product Type and Application
  8. 3.8 Global Vaginosis Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Vaginosis Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Vaginosis Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Vaginosis Drug Market by Type
  1. 4.1 Vaginosis Drug Type Introduction
  2. 4.1.1 Rx
  3. 4.1.2 OTC
  4. 4.2 Global Vaginosis Drug Sales Volume by Type
  5. 4.2.1 Global Vaginosis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Vaginosis Drug Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Vaginosis Drug Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Vaginosis Drug Sales Value by Type
  9. 4.3.1 Global Vaginosis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Vaginosis Drug Sales Value by Type (2021-2032)
  11. 4.3.3 Global Vaginosis Drug Sales Value Share by Type (2021-2032)
5 Vaginosis Drug Market by Application
  1. 5.1 Vaginosis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Vaginosis Drug Sales Volume by Application
  6. 5.2.1 Global Vaginosis Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vaginosis Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Vaginosis Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Vaginosis Drug Sales Value by Application
  10. 5.3.1 Global Vaginosis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Vaginosis Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Vaginosis Drug Sales Value Share by Application (2021-2032)
6 Vaginosis Drug Regional Sales and Value Analysis
  1. 6.1 Global Vaginosis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaginosis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Vaginosis Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Vaginosis Drug Sales by Region (2027-2032)
  5. 6.3 Global Vaginosis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Vaginosis Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Vaginosis Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Vaginosis Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Vaginosis Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Vaginosis Drug Sales Value (2021-2032)
  12. 6.6.2 North America Vaginosis Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Vaginosis Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Vaginosis Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Vaginosis Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Vaginosis Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Vaginosis Drug Sales Value (2021-2032)
  21. 6.9.2 South America Vaginosis Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Vaginosis Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Vaginosis Drug Sales Value Share by Country, 2025 VS 2032
7 Vaginosis Drug Country-level Sales and Value Analysis
  1. 7.1 Global Vaginosis Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vaginosis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Vaginosis Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Vaginosis Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Vaginosis Drug Sales by Country (2027-2032)
  6. 7.4 Global Vaginosis Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Vaginosis Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Vaginosis Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Vaginosis Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Vaginosis Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Vaginosis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Vaginosis Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Vaginosis Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Vaginosis Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Vaginosis Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Vaginosis Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Vaginosis Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Vaginosis Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Vaginosis Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Vaginosis Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Vaginosis Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Vaginosis Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Vaginosis Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Vaginosis Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Vaginosis Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Vaginosis Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Vaginosis Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Vaginosis Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Vaginosis Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Vaginosis Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Vaginosis Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Vaginosis Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Vaginosis Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Vaginosis Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Vaginosis Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Vaginosis Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Vaginosis Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Vaginosis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yunnan Baiyao
  2. 8.1.1 Yunnan Baiyao Company Information
  3. 8.1.2 Yunnan Baiyao Business Overview
  4. 8.1.3 Yunnan Baiyao Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Yunnan Baiyao Vaginosis Drug Product Portfolio
  6. 8.1.5 Yunnan Baiyao Recent Developments
  7. 8.2 Abbott
  8. 8.2.1 Abbott Company Information
  9. 8.2.2 Abbott Business Overview
  10. 8.2.3 Abbott Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Abbott Vaginosis Drug Product Portfolio
  12. 8.2.5 Abbott Recent Developments
  13. 8.3 Xiuzheng
  14. 8.3.1 Xiuzheng Company Information
  15. 8.3.2 Xiuzheng Business Overview
  16. 8.3.3 Xiuzheng Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Xiuzheng Vaginosis Drug Product Portfolio
  18. 8.3.5 Xiuzheng Recent Developments
  19. 8.4 Teva
  20. 8.4.1 Teva Company Information
  21. 8.4.2 Teva Business Overview
  22. 8.4.3 Teva Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Teva Vaginosis Drug Product Portfolio
  24. 8.4.5 Teva Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Vaginosis Drug Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Vaginosis Drug Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Bayer
  38. 8.7.1 Bayer Company Information
  39. 8.7.2 Bayer Business Overview
  40. 8.7.3 Bayer Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Bayer Vaginosis Drug Product Portfolio
  42. 8.7.5 Bayer Recent Developments
  43. 8.8 West-Ward
  44. 8.8.1 West-Ward Company Information
  45. 8.8.2 West-Ward Business Overview
  46. 8.8.3 West-Ward Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 West-Ward Vaginosis Drug Product Portfolio
  48. 8.8.5 West-Ward Recent Developments
  49. 8.9 Starpharma
  50. 8.9.1 Starpharma Company Information
  51. 8.9.2 Starpharma Business Overview
  52. 8.9.3 Starpharma Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Starpharma Vaginosis Drug Product Portfolio
  54. 8.9.5 Starpharma Recent Developments
  55. 8.10 Piramal
  56. 8.10.1 Piramal Company Information
  57. 8.10.2 Piramal Business Overview
  58. 8.10.3 Piramal Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Piramal Vaginosis Drug Product Portfolio
  60. 8.10.5 Piramal Recent Developments
  61. 8.11 Perrigo
  62. 8.11.1 Perrigo Company Information
  63. 8.11.2 Perrigo Business Overview
  64. 8.11.3 Perrigo Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Perrigo Vaginosis Drug Product Portfolio
  66. 8.11.5 Perrigo Recent Developments
  67. 8.12 Novel
  68. 8.12.1 Novel Company Information
  69. 8.12.2 Novel Business Overview
  70. 8.12.3 Novel Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Novel Vaginosis Drug Product Portfolio
  72. 8.12.5 Novel Recent Developments
  73. 8.13 Mission
  74. 8.13.1 Mission Company Information
  75. 8.13.2 Mission Business Overview
  76. 8.13.3 Mission Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Mission Vaginosis Drug Product Portfolio
  78. 8.13.5 Mission Recent Developments
  79. 8.14 HPGC
  80. 8.14.1 HPGC Company Information
  81. 8.14.2 HPGC Business Overview
  82. 8.14.3 HPGC Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 HPGC Vaginosis Drug Product Portfolio
  84. 8.14.5 HPGC Recent Developments
  85. 8.15 Galderma
  86. 8.15.1 Galderma Company Information
  87. 8.15.2 Galderma Business Overview
  88. 8.15.3 Galderma Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Galderma Vaginosis Drug Product Portfolio
  90. 8.15.5 Galderma Recent Developments
  91. 8.16 Edenvridge
  92. 8.16.1 Edenvridge Company Information
  93. 8.16.2 Edenvridge Business Overview
  94. 8.16.3 Edenvridge Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Edenvridge Vaginosis Drug Product Portfolio
  96. 8.16.5 Edenvridge Recent Developments
  97. 8.17 Alkem
  98. 8.17.1 Alkem Company Information
  99. 8.17.2 Alkem Business Overview
  100. 8.17.3 Alkem Vaginosis Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Alkem Vaginosis Drug Product Portfolio
  102. 8.17.5 Alkem Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vaginosis Drug Value Chain Analysis
  2. 9.1.1 Vaginosis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vaginosis Drug Sales Mode & Process
  6. 9.2 Vaginosis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vaginosis Drug Distributors
  9. 9.2.3 Vaginosis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst